Trastuzumab achieves slight reduction in recurrence for women with HER2-positive DCIS

The addition of the monoclonal antibody therapy Trastuzumab to radiotherapy did not reach the protocol objective of a 36% reduction in the ipsilateral breast tumor recurrence rate for women with HER2-positive ductal carcinoma in situ (DCIS) on the NRG Oncology clinical trial NSABP B-43. The trial did find a statistically non-significant, modest (19%) reduction in…

Details

Trastuzumab combined with trimodality treatment does not improve outcomes for patients

Results of the NRG Oncology clinical trial RTOG 1010 indicated that the addition of the monoclonal antibody trastuzumab to neoadjuvant trimodality treatment did not improve disease-free survival (DFS) outcomes for patient with HER2 overexpressing local and locally advanced esophageal adenocarcinoma. These results were recently, orally presented during the virtual Annual Meeting of the American Society…

Details

Using brain imaging to demonstrate weaker neural suppression for those with autism

MINNEAPOLIS, MN- May 29, 2020 – According to the National Autism Association, people with autism spectrum disorder (ASD) may experience sensory hypersensitivity. A University of Minnesota Medical School researcher recently published an article in Nature Communications that illustrates why that may be true by showing the differences in visual motion perception in ASD are accompanied…

Details

Combined cediranib and olaparib presents similar activity to standard of care treatment

Results of the NRG Oncology phase III clinical trial NRG-GY004 indicated that the addition of the investigational agent cediranib to olaparib and standard platinum-based chemotherapy did not improve progression-free survival (PFS) outcomes for women with platinum-sensitive ovarian cancer;, however, activity between the treatments were similar in patients. These results were recently presented at the virtual…

Details